Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
about
Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogsCan lenalidomide play a role in the management of scleritis?Novel agents in indolent lymphomas.Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
P2860
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
@ast
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
@en
Update on immunomodulatory drugs
@nl
type
label
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
@ast
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
@en
Update on immunomodulatory drugs
@nl
prefLabel
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
@ast
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
@en
Update on immunomodulatory drugs
@nl
P2093
P2860
P1476
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
@en
P2093
Dirk Jaeger
Klaus Podar
Mathias Witzens-Harig
Sonia Vallet
P2860
P304
P356
10.1517/14656566.2012.656091
P407
P577
2012-02-13T00:00:00Z